Pain being an unpleasant sensation, is an ill defined, disabling accompaniment of many medical conditions and is often evoked by an external or internal noxious stimulus, with a major affective component. The principal objective of alleviating pain is to remove the cause of pain, but it is not always possible to do so, hence, analgesics are used for the symptomatic treatment of pain.\[[@ref1]\]

Although, patients with chronic pain are being treated with various medications such as tricyclic antidepressants (TCA), non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and opioids, none has shown outstanding efficacy.

Depression and a feeling of hopelessness are common accompaniments of chronic pain.\[[@ref2]\] It has also been proved in about 75% of the studies that some antidepressants are superior to placebo in alleviating pain as they have some intrinsic analgesic activity.\[[@ref3]\] A wide range of painful conditions are responsive to antidepressants and they have been used as co-analgesics in various clinical conditions, particularly diabetic neuropathy pain, rheumatoid arthritis and migraine.\[[@ref4]\] Antidepressants with noradrenergic reuptake inhibition properties (TCA) have been reported to produce varying degrees of pain relief in several persistent or chronic pain syndromes in humans, namely, diabetic neuropathy,\[[@ref5]\] post-herpetic neuralgia,\[[@ref6]\] fibromyalgia,\[[@ref7]\] and chronic rheumatic pain.\[[@ref8]\] Unfortunately, adverse effects are not uncommon during antidepressant use, particularly with TCA.\[[@ref2][@ref8]--[@ref10]\] Yet even after forty years of extensive research on the efficacy of antidepressant drugs in the management of chronic pain, their use has not become common.\[[@ref9]\]

In recent times, numerous open and controlled studies have shown antidepressant drugs to have an analgesic activity, especially, selective serotonin reuptake inhibitors (SSRIs), which are effective in mixed and chronic pain.\[[@ref11]\] On the other hand, there are some studies that have altogather denied the analgesic role of SSRI.\[[@ref5][@ref12][@ref13]\]

Another intriguing aspect is the meager understanding regarding their mechanism of action. The underlying mechanisms for the Antinociceptive activity of these agents probably involve a complex interaction between several neurotransmitter systems and neuroreceptors.\[[@ref14]\] There is ample evidence to suggest that the pain inhibitory pathway involves monoamines such as noradrenalin (NA) and 5-hydroxy tryptamine (5-HT),\[[@ref15]\] and SSRI, by increasing the serotonin level, may inhibit the release of the neurotransmitter carrying the pain sensation from nerve endings.\[[@ref16]\]

Despite such an enormity of literature, it is not yet clear whether these can be used as analgesics, and if so, what could be the underlying mechanism. Therefore, the present study was planned with the aim of: (1) Confirming the analgesic/antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazapine), (2) Studying the interaction of these drugs with morphine, and (3) Delineating their probable site of action.

Materials and Methods {#sec1-1}
=====================

The study was conducted on healthy albino mice (25 -- 35 g) of either sex, maintained at an ambient temperature of 25 -- 35°C with food and water ad libitum. The experimental protocol was approved by the Institutional Animal Ethics Committee and was executed according to the guidelines of the committee for the purpose of control and supervision of the experiments on animals (CPCSEA), India.

The animals were divided into 20 groups of six each. Individual test drug was given to find its subanalgesic dose. Mice in groups 1, 2, and 3 received fluoxetine (2, 5, and 10 mg/kg, respectively), groups 4, 5, and 6 received venlafaxine (30, 40, and 50 mg/kg, respectively), group 7, 8, and 9 received mirtazapine (3, 5, and 7 mg/kg, respectively), group 10, 11, and 12 received escitalopram (2.5, 5, and 10 mg/kg, respectively), and group 13 and 14 received morphine (0.5 and 1 mg/kg). Groups 15, 16, and 17 received combined treatment consisting of subanalgesic doses of test drugs with subanalgesic dose of morphine, that is, fluoxetine (2 mg/kg), venlafaxine (30 mg/kg), and mirtazapine (3 mg/kg), with morphine (0.5 mg/kg), respectively. Groups 18, 19, and 20 received fluoxetine (5 mg/kg), venlafaxine (40 mg/kg), and mirtazapine (5 mg/kg) 10 minutes before naloxone (1 mg/kg). Naloxone was given 10 minutes after the test drug. All the drugs were given subcutaneously. In the groups that received combined treatment, both the drugs were administered simultaneously, at different sites.

Determination of the antinociceptive activity {#sec2-1}
---------------------------------------------

Effect of test drugs was obtained in terms of tail flick latency period (the time required for flicking of tail, i.e., reaction time), using an analgesiometer at 0, 15, 30, 60, and 120 minutes. Radiant heat was directed to the proximal third of the tail through a hot wire of the analgesiometer and the reaction time was noted, when the mouse tried to pull the tail away. A mean of two pre-drug readings was taken as the basal value (0 minute). Mice with a reaction time of more than six seconds were not used in the test. In order to prevent tissue injury, a cut off time of 10 seconds was maintained. The cut off time was considered as the latency period for the animals not responding up to 10 seconds.

Statistical analysis {#sec2-2}
--------------------

The results were expressed as mean ± SD; the paired Student\'s '*t*' test was employed for comparison between the two means as a measure of significance. *P* value of \<0.05 was regarded as a statistically significant value.

Results {#sec1-2}
=======

Effect of test drugs on tail flick latency {#sec2-3}
------------------------------------------

Fluoxetine (2 mg/kg), venlafaxine (30 mg/kg), and mirtazapine (3 mg/kg) showed no significant increase in tail flick latency period as compared to the corresponding 0 minute values in mice, on the tail flick analgesiometer. Fluoxetine (5 and 10 mg/kg), venlafaxine (40 and 50 mg/kg), and mirtazapine (5 and 7 mg/kg) produced a significant increase in tail flick latency at all time intervals (*P* \< 0.05). These drugs produced a dose-dependent antinociception, but escitalopram did not show any antinociceptive effect at 2.5, 5, and 10 mg/kg doses \[[Table 1](#T1){ref-type="table"}\].

###### 

Effects of different test drugs on the tail.flick latency period (seconds; mean ± SD) at different time intervals
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Effect of morphine treatment {#sec2-4}
----------------------------

Morphine (0.5 mg/kg) showed no significant increase in tail flick latency period at any time interval (*P* \> 0.1). However, at a dose of 1 mg/kg, morphine produced a significant increase in tail flick latency at every time interval tested, from 0 to 120 minutes (*P* \< 0.001) \[[Table 1](#T1){ref-type="table"}\].

Effects of combined treatment {#sec2-5}
-----------------------------

The combination of subanalgesic doses of fluoxetine (2 mg/kg), venlafaxine (30 mg/kg), and mirtazapine (3 mg/kg), with morphine (0.5 mg/kg), respectively, produced a significant (*P* \< 0.01 to *P* \< 0.001) increase in the tail flick latency period, throughout the study \[[Table 2](#T2){ref-type="table"}\].

###### 

Effects on the tail.flick latency period (seconds; mean ± SD) after combined treatment of test drugs with morphine at different time intervals
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The combination of fluoxetine (5 and 10 mg/kg), venlafaxine (40 and 50 mg/kg), and mirtazapine (5 and 7 mg/kg), with naloxone (1 mg/kg) did not produce significant (*P* \> 0.1) increase in tail flick latency during the entire test period, \[[Table 3](#T3){ref-type="table"}\]. This shows that pretreatment with naloxone (1 mg/kg) completely antagonized the antinociceptive effect of fluoxetine, venlafaxine, and mirtazapine, at their analgesic doses.

###### 

Effects on the tail. flick latency period (seconds; mean ± SD) after combined treatment of test drugs with naloxone
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Discussion {#sec1-3}
==========

Chronic pain is not only difficult for patients to tolerate, but also for the clinicians to treat effectively. Several pre-clinical and clinical studies have reported the antinociceptive activity of antidepressants.\[[@ref4]--[@ref8][@ref11]--[@ref13]\]

In the present study, SSRIs (fluoxetine and escitalopram) and atypical antidepressants (mirtazapine and venlafaxine) were used to analyze their analgesic/antinociceptive effect, using the tail-flick analgesiometer. Out of the four above-mentioned drugs, escitalopram did not show any analgesic/antinociceptive effect. Our observations are in accordance with the results of various clinical and animal studies.\[[@ref12][@ref13]\]

Fluoxetine showed antinociceptive activity at 5 and 10 mg/kg. These findings are in conjunction with the finding of Max *et al*.,\[[@ref5]\] \[[Table 4](#T4){ref-type="table"}\] who in a double blind cross-over study, observed similar results. Goldenberg *et al*.,\[[@ref17]\] compared placebo with fluoxetine in fibromyalgia patients and found a significant pain-reliving activity in fluoxetine. Similarly, Rani *et al*.,\[[@ref8]\] compared fluoxetine with amitriptyline and placebo in patients with chronic rheumatic pain and found significant reduction in pain intensity scores and pain relief scores. They suggested fluoxetine to be an effective analgesic, with fewer side effects.

###### 

Various studies showing antinociceptive activity of antidepressants
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The antinociceptive effect shown by mirtazapine (5 and 7 mg/kg) is supported by the findings of Brannon and Stone\[[@ref18]\] for chronic back pain, with major depression. Muth-Selbach *et al*.,\[[@ref19]\] and Bomholt *et al*.,\[[@ref13]\] also showed the same effects in animal models.

In our study, venlafaxine showed an antinociceptive effect at 40 and 50 mg/kg. Various other studies also suggested the antinociceptive effect of venlafaxine, namely, Lang *et al*.,\[[@ref20]\] in mitigating thermal hyperalgesia in animals, Songer and Schulte\[[@ref21]\] in radicular back pain associated with depression, Bradley *et al*.,\[[@ref22]\] in migraine, chronic back pain, and chronic regional pain syndrome (CRPS), and Dwight *et al*.,\[[@ref23]\] in fibromyalgia with axis I psychiatric disorders.

Further, morphine at a subanalgesic dose (0.5 mg/kg) potentiated all the three above-mentioned antidepressants (supported by the work of Suh and Tseng and Erjavec *et al*.,)\[[@ref24][@ref25]\]

Naloxone (1 mg/kg) abolished the analgesic effect of fluoxetine, mirtazapine, and venlafaxine. These results suggest that the antinociceptive activity of these three antidepressant drugs could involve opioid mechanisms. These observations are in agreement with the findings of Singh et al., and Anjaneyulu and Chopra \[[Table 4](#T4){ref-type="table"}\].\[[@ref4][@ref26]\]

As the analgesic activity of morphine is mediated through mue (*μ*) receptors, it is likely that fluoxetine, mirtazapine, and venlafaxine act through opioid pathways involving the *μ* opioid receptors. However, these drugs interact with other receptor systems also, such as, cholinergic, muscarinic, histaminergic, noradrenergic, and even the GABAergic system.\[[@ref26]--[@ref28]\] Hence, it would not be unreasonable to suggest that antidepressant drugs would involve at least some of these systems for their analgesic effect.

In the present study, a combination of subanalgesic doses of morphine and fluoxetine, mirtazapine, and venlafaxine produced a significant additive antinociceptive/analgesic effect. Therefore, the above combinations of antidepressants with morphine would theoretically minimize the dose requirements, and thus, the potential adverse effects of morphine. Above all, further clinical studies are needed to prove the same.
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